(Q38351502)

2 September 2017

1 reference

title

Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? (English)

1 reference

2 September 2017

Timo T Schmidt

2

0 references

author name string

Tomislav Majić

series ordinal

1

1 reference

PubMed ID

25670401

2 September 2017

Jürgen Gallinat

series ordinal

3

1 reference

PubMed ID

25670401

2 September 2017

language of work or name

English

0 references

publication date

9 February 2015

1 reference

Journal of Psychopharmacology

2 September 2017

1 reference

2 September 2017

29

1 reference

2 September 2017

3

1 reference

2 September 2017

241-253

1 reference

Ketamine for depression: where do we go from here?

2 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Serotonin model of schizophrenia: emerging role of glutamate mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Peyote in the treatment of alcoholism among American Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Treatment of acute opioid withdrawal with ibogaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Sociopsychotherapeutic functions of ayahuasca healing in Amazonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Canonical microcircuits for predictive coding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Effects of ketamine in treatment-refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

LSD treatment in a severe case of compulsive neurosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The neurophenomenology of neutral hypnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

From prediction error to psychosis: ketamine as a pharmacological model of delusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Therapeutic infusions of ketamine: do the psychoactive effects matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Comparison of the LSD-25 experience and delirium tremens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

A theory of cortical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Neurophysiological effects of cannabinoids: implications for psychosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Spirituality-based recovery from drug addiction in the twelve-step fellowship of narcotics anonymous

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Serotonin research: contributions to understanding psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Hallucinogens as medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

21 January 2018

Hallucinogens: An update

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psychological and cognitive effects of long-term peyote use among Native Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psychedelic Agents in Creative Problem-Solving: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Spirituality in recovery: a lagged mediational analysis of alcoholics anonymous' principal theoretical mechanism of behavior change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

THE HYPNOTIC TRANCE, THE PSYCHEDELIC EXPERIENCE, AND THE CREATIVE ACT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The persistence of the subjective in neuropsychopharmacology: observations of contemporary hallucinogen research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Hallucinogen actions on human brain revealed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Functional MRI and the study of human consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

A clinical study of LSD treatment in alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Long Lasting Effects of LSD on Normals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Treatment of alcoholism using psychedelic drugs: a review of the program of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Complex stimulus properties of LSD: a drug discrimination study with alpha 2-adrenoceptor agonists and antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Medication development of ibogaine as a pharmacotherapy for drug dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Current status of ketamine and related compounds for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Effects of Psilocybe argentipes on marble-burying behavior in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Hallucinogenic drugs and plants in psychotherapy and shamanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Broadband cortical desynchronization underlies the human psychedelic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Hallucinogenic plant use and related indigenous belief systems in the ecuadorian amazon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

A review of the clinical effects of psychotomimetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The pharmacology of lysergic acid diethylamide: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The pharmacology of psilocybin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Modeling ketamine effects on synaptic plasticity during the mismatch negativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Response of cluster headache to psilocybin and LSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Prediction of psilocybin response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Psychedelics and Religious Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

Enhancing action of LSD on neuronal responsiveness to serotonin in a brain structure involved in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881114568040

21 January 2018

Identifiers

DOI

10.1177/0269881114568040

1 reference

2 September 2017

1 reference

PubMed ID

25670401